Bausch Health Cos Inc. $BHC Shares Acquired by Viewpoint Capital Management LLC

Viewpoint Capital Management LLC increased its stake in shares of Bausch Health Cos Inc. (NYSE:BHC) by 20.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 28,900 shares of the company’s stock after acquiring an additional 4,900 shares during the period. Viewpoint Capital Management LLC’s holdings in Bausch Health Cos were worth $192,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its position in shares of Bausch Health Cos by 4,134.7% during the first quarter. Acadian Asset Management LLC now owns 673,316 shares of the company’s stock worth $4,347,000 after acquiring an additional 657,416 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Bausch Health Cos by 97.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after purchasing an additional 467,270 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Bausch Health Cos by 162.9% in the first quarter. Cubist Systematic Strategies LLC now owns 607,656 shares of the company’s stock valued at $3,933,000 after purchasing an additional 376,518 shares during the period. Nomura Holdings Inc. raised its holdings in shares of Bausch Health Cos by 106.2% during the first quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock valued at $151,366,000 after buying an additional 12,050,000 shares during the last quarter. Finally, Federated Hermes Inc. bought a new stake in shares of Bausch Health Cos during the first quarter valued at approximately $758,000. 78.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BHC shares. Weiss Ratings reissued a “hold (c)” rating on shares of Bausch Health Cos in a report on Saturday, September 27th. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 20th. Four research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.00.

Insiders Place Their Bets

In other Bausch Health Cos news, Director John Paulson acquired 34,721,118 shares of Bausch Health Cos stock in a transaction dated Thursday, August 14th. The stock was bought at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the transaction, the director owned 70,755,869 shares in the company, valued at approximately $636,802,821. This trade represents a 96.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have bought 37,964,167 shares of company stock valued at $333,757,793. 19.97% of the stock is currently owned by corporate insiders.

Bausch Health Cos Stock Performance

BHC opened at $6.48 on Tuesday. The business has a 50 day moving average price of $6.91 and a two-hundred day moving average price of $6.04. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of 24.92 and a beta of 0.43. Bausch Health Cos Inc. has a 1-year low of $4.25 and a 1-year high of $9.85.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.07). The firm had revenue of $2.57 billion during the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. Bausch Health Cos has set its FY 2025 guidance at EPS. Research analysts predict that Bausch Health Cos Inc. will post 4.41 EPS for the current fiscal year.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.